|Bid||38.90 x 100|
|Ask||39.42 x 400|
|Day's Range||39.17 - 39.41|
|52 Week Range||37.20 - 44.54|
|PE Ratio (TTM)||44.28|
|Dividend & Yield||1.99 (5.13%)|
|1y Target Est||N/A|
Despite the success of new products, GlaxoSmithKline plc (GSK) believes that its overall performance has been weaker than it would have liked.
The Zacks Analyst Blog Highlights: Allergan, Ecolab, Exelon, GlaxoSmithKline and Rockwell Collins
Perrigo (PRGO) gains an FDA consent for the OTC version of AstraZeneca's Nexium post the ongoing patent lawsuit settlement through an agreement.